

July 30, 2020

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	---

Dear Sirs,

Sub: Press Release

Please find enclosed the Press Release on the financial results for the quarter ended June 30, 2020.

Please take the information on record.

Thanking you,

Yours sincerely,
For Laurus Labs Limited


G. Venkateswar Reddy
Company Secretary



Encl: As above

Strong Revenue growth of 77% and PAT growth of 1047%

Q1 FY21 Revenues up 77%

Q1 FY21 EBITDA at ₹ 285 crs up 228%, Margins at 29%

Q1 FY21 PAT at ₹ 172 crs margins at 18%

Hyderabad, July 30, 2020: Laurus Labs Ltd. (Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01010), a leading research and development-driven pharmaceutical company in India announces its Q1 FY21 results.

Consolidated Q1 FY21 Laurus reported:

- Revenue at ₹ 974 crs, up 77 % (Y-o-Y)
- EBITDA ₹ 285 crs, up 228% (Y-o-Y)
- EBITDA margins at 29%
- PAT at ₹ 172 crs, up 1047% (Y-o-Y)
- EPS (Diluted) for the period at ₹ 16.1 per share (not annualised), up by 1050% (Y-o-Y)

Commenting on the results announcement, Dr. Satyanarayana Chava – Founder & CEO said;

"I am very happy to share that we have started the new Financial year on a very strong note. Despite the challenges posed by COVID-19 we have clocked a Revenue growth of 77% in the quarter. Our EBITDA has grown over 2 times and our profitability also improved significantly to ₹ 172 crs.

Our Formulations business continues to grow at a higher rate mainly led by higher LMIC business, the revenue contribution from Formulations division has now grown to 36%. Custom Synthesis business has maintained its growth trajectory with strong contribution from all the divisional segments. Our Anti – Viral API portfolio has showcased a strong Revenue growth of 19% on the back of higher volumes and offtake in EFV & TDF along with launch of DTG to Third Parties. The Other API business segment continues to post healthy growth with improved volumes.

We entered the new Financial year with uncertainties of COVID-19, as an Organization we have been highly vigilant and responsive to the safety and well being of all our Employees. With our integrated strategy in place and continued investment in sustainable long term growth I am very optimistic on delivering superior performance on all parameters."

Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said;

“Our Total Revenues from Operations came in at ₹ 974 crs. With improved operating leverage and change in product mix, our Gross Margin showcased improvement to 54%. Our EBITDA margins showed improvement at 29% on the back of higher Gross Margins and improved Operating Leverage.

With better operational performance our ROCE on annualised basis has improved to 32%. Given the improvement in business environment we continue to undertake brown field Capex programme for all our divisions. We are confident that the new capex will have shorter payback period and will be ROCE accretive in coming years.”

Business Highlights:

Overall

- Total Income at ₹ 974 crs in Q1 FY21 Up 77 % (Y-o-Y)
- R & D spent of ₹ 42 Cr and 4.3% of sales in Q1 FY21.

Generic FDF

- Revenue showcased growth of 232% (Y-o-Y)
- Generic FDF business maintains robust growth momentum for the quarter.
 - The growth in the quarter was led by higher sales from tender business in LMIC; having a strong order book for coming quarters
 - North America business also improved on the back of higher sales and launch of HCQS
 - Contract manufacturing revenues from EU region has a strong order book for FY21 and beyond
- 1 product validation completed for formulation apart from filling of 26 ANDAs & NDAs
- 8 products received Final Approvals and 5 products have received Tentative Approvals
- Acquired Aspen's South African Subsidiary, in order to get a foothold in South Africa's large ARV market

Synthesis & Ingredients

- Revenue showcased growth of 37% (Y-o-Y)
- Total Number of Active Projects in the CDMO division stood at 47 as on Q1 FY21
- State-of-the-art cGMP facilities to manufacture NCEs and Intermediates
- Working with Large Global Innovator Pharmaceutical Companies, mid and small Biotech Companies
- Incorporated Wholly Owned Subsidiary Laurus Synthesis Private Limited (LSPL) to have increased focus and eventually dedicated R&D and Manufacturing. Part of this strategy, acquired manufacturing Unit in Vizag.

Generic API

- Revenue from Generic API segment showcased growth of 40%
- The Anti-Viral segment showed growth of 19% and expect to have growth for the full year
- In the Other API segment - Contract manufacturing of Generic APIs showing robust growth of more than 2 times
- Filed 262 patent applications and 121 patent granted as on June 30, 2020

-ENDS-

About Laurus Labs Limited

Laurus Labs is a leading research driven Pharmaceutical Manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma, and Gastroenterology. We are thriving on growth opportunities in formulation manufacturing to service all leading markets of North America, Europe and Low Middle-Income Countries (LMIC). We are driving growth opportunities in Contract Development and Manufacturing through our Synthesis business. Most of our manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA, etc. Our approach remains to identify and invest ahead of time with strategic investments in State-of-the-Art R&D and Manufacturing Infrastructure enabling us to become a quality supplier of high volume products. **Corporate Identification No: L24239AP2005PLC047518**

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

Pavan Kumar N

Laurus Labs Ltd.

Tel:+91 40 6659 4380/ +919246564666/ 7337353848

Email: mediarelations@lauruslabs.com

DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.